|
US6346611B1
(en)
|
1990-06-11 |
2002-02-12 |
Gilead Sciences, Inc. |
High affinity TGfβ nucleic acid ligands and inhibitors
|
|
US6395888B1
(en)
|
1996-02-01 |
2002-05-28 |
Gilead Sciences, Inc. |
High affinity nucleic acid ligands of complement system proteins
|
|
US6232071B1
(en)
*
|
1990-06-11 |
2001-05-15 |
Gilead Sciences, Inc. |
Tenascin-C nucleic acid ligands
|
|
US6762290B1
(en)
|
1999-07-29 |
2004-07-13 |
Gilead Sciences, Inc. |
High affinity vascular endothelial growth factor (VEGF) receptor nucleic acid ligands and inhibitors
|
|
AU782620B2
(en)
*
|
1991-06-10 |
2005-08-11 |
Gilead Sciences, Inc. |
High affinity vascular endothelial growth factor (VEGF) receptor nucleic acid ligands and inhibitors
|
|
US7087411B2
(en)
*
|
1999-06-08 |
2006-08-08 |
Regeneron Pharmaceuticals, Inc. |
Fusion protein capable of binding VEGF
|
|
ATE317869T1
(de)
*
|
1999-07-14 |
2006-03-15 |
Alza Corp |
Neutrales lipopolymer und liposomale zusammensetzungen daraus
|
|
CA2425208C
(en)
*
|
2000-09-26 |
2013-04-09 |
Duke University |
Rna aptamers and methods for identifying the same
|
|
DK1438321T5
(da)
*
|
2001-10-26 |
2011-02-21 |
Noxxon Pharma Ag |
Modificeret L-nukleinsyre
|
|
HRP20040406A2
(en)
*
|
2001-11-09 |
2005-02-28 |
Eyetech Pharmaceuticals |
Methods for treating ocular neovascular diseases
|
|
US7094410B2
(en)
*
|
2002-03-02 |
2006-08-22 |
The Scripps Research Institute |
DNA vaccine against proliferating endothelial cells and methods of use thereof
|
|
US7767803B2
(en)
|
2002-06-18 |
2010-08-03 |
Archemix Corp. |
Stabilized aptamers to PSMA and their use as prostate cancer therapeutics
|
|
WO2004012773A1
(en)
*
|
2002-07-24 |
2004-02-12 |
F. Hoffmann-La Roche Ag |
Polyalkylene glycol acid additives
|
|
JP2005533862A
(ja)
|
2002-07-25 |
2005-11-10 |
アーケミックス コーポレイション |
調節されたアプタマー治療剤
|
|
US9303262B2
(en)
|
2002-09-17 |
2016-04-05 |
Archemix Llc |
Methods for identifying aptamer regulators
|
|
US8039443B2
(en)
|
2002-11-21 |
2011-10-18 |
Archemix Corporation |
Stabilized aptamers to platelet derived growth factor and their use as oncology therapeutics
|
|
US10100316B2
(en)
|
2002-11-21 |
2018-10-16 |
Archemix Llc |
Aptamers comprising CPG motifs
|
|
US8853376B2
(en)
|
2002-11-21 |
2014-10-07 |
Archemix Llc |
Stabilized aptamers to platelet derived growth factor and their use as oncology therapeutics
|
|
WO2006050498A2
(en)
|
2004-11-02 |
2006-05-11 |
Archemix Corp. |
Stabilized aptamers to platelet derived growth factor and their use as oncology therapeutics
|
|
US20040197804A1
(en)
|
2002-12-03 |
2004-10-07 |
Keefe Anthony D. |
Method for in vitro selection of 2'-substituted nucleic acids
|
|
RU2234097C1
(ru)
*
|
2003-03-05 |
2004-08-10 |
Московский областной научно-исследовательский клинический институт |
Способ диагностики саркомы капоши
|
|
FR2852606A1
(fr)
*
|
2003-03-18 |
2004-09-24 |
Inst Nat Sante Rech Med |
Moyens pour inhiber simultanement l'expression de plusieurs genes impliques dans une pathologie
|
|
EP1620547B1
(en)
|
2003-04-21 |
2014-06-18 |
Archemix LLC |
Stabilized aptamers to platelet derived growth factor and their use as oncology therapeutics
|
|
CL2004001996A1
(es)
*
|
2003-08-08 |
2005-05-06 |
Eyetech Pharmaceuticals Inc |
Aptameros anti-vegf (factor de crecimiento endotelial vascular) con bloqueo nucleotidico 5'-5' o 3'-3' invertido, composicion que lo contiene, util para trastornos de neovascularizacion.
|
|
HUE050481T2
(hu)
|
2004-02-12 |
2020-12-28 |
Archemix Llc |
Aptamer terapeutikumok, amelyek használhatók komplementtel kapcsolatos rendellenességek kezelésében
|
|
US7803931B2
(en)
|
2004-02-12 |
2010-09-28 |
Archemix Corp. |
Aptamer therapeutics useful in the treatment of complement-related disorders
|
|
BRPI0509911A
(pt)
*
|
2004-04-13 |
2007-09-18 |
Osi Eyetech Inc |
método para inibir a atividade de um sìtio separado de um sìtio de ligação de aptámero em um ligando, métodos para aumentar a faixa antagonista, de receptor de um aptámero de ligação de ligando, do ligando de um aptámero de ligação de receptor, de receptor de um aptámero de vegf, e do ligando de um aptámero de vegfr, método para aumentar uma propriedade antagonista de um aptámero que alveja uma proteìna que interage com uma segunda proteìna, método para identificar um conjugado de aptámero, composto, métodos para liberar uma molécula biologicamente ativa, ácido nucléico, um aptámero, e um aptámero anti-vegf a um olho, composto, composição para liberar uma molécula biologicamente ativa a um olho
|
|
US7579450B2
(en)
|
2004-04-26 |
2009-08-25 |
Archemix Corp. |
Nucleic acid ligands specific to immunoglobulin E and their use as atopic disease therapeutics
|
|
US7566701B2
(en)
|
2004-09-07 |
2009-07-28 |
Archemix Corp. |
Aptamers to von Willebrand Factor and their use as thrombotic disease therapeutics
|
|
CA2578046A1
(en)
|
2004-09-07 |
2006-03-16 |
Archemix Corp. |
Aptamer medicinal chemistry
|
|
US8101385B2
(en)
|
2005-06-30 |
2012-01-24 |
Archemix Corp. |
Materials and methods for the generation of transcripts comprising modified nucleotides
|
|
EP1907590B1
(en)
|
2005-06-30 |
2012-09-19 |
Archemix LLC |
T7 rna polymerase and methods for the generation of fully 2'-modified nucleic acid transcripts
|
|
WO2007016380A2
(en)
*
|
2005-07-28 |
2007-02-08 |
(Osi) Eyetech, Inc. |
Cyclitol linker polymer conjugate
|
|
CA2620182A1
(en)
|
2005-08-22 |
2007-03-01 |
Dennis A. Carson |
Tlr agonists
|
|
KR100877824B1
(ko)
|
2005-11-11 |
2009-01-12 |
한국생명공학연구원 |
Ｅ2ｅｐｆ ｕｃｐ-ｖｈｌ 상호작용 및 그 용도
|
|
JP2009518024A
(ja)
*
|
2005-12-06 |
2009-05-07 |
ドマンティス リミテッド |
Ｅｇｆｒおよび／またはｖｅｇｆに対して結合特異性を有するリガンドおよびその使用法
|
|
WO2007069068A2
(en)
*
|
2005-12-16 |
2007-06-21 |
Diatos |
Cell penetrating peptide conjugates for delivering nucleic acids into cells
|
|
EP1970078A4
(en)
*
|
2006-01-11 |
2010-11-17 |
Kyowa Hakko Kirin Co Ltd |
COMPOSITION INHIBITING THE EXPRESSION OF A TARGET GENE OF THE OCULAR GLOBE AND REMEDY FOR OCULAR GLOBE DISEASE
|
|
CA3009846C
(en)
|
2006-03-08 |
2021-08-31 |
David Epstein |
Complement binding aptamers and anti-c5 agents useful in the treatment of ocular disorders
|
|
ES2552471T3
(es)
|
2007-02-07 |
2015-11-30 |
The Regents Of The University Of California |
Conjugados de agonistas de TLR sintéticos y usos de los mismos
|
|
WO2009137095A2
(en)
|
2008-05-08 |
2009-11-12 |
The Johns Hopkins University |
Compositions and methods for modulating an immune response
|
|
RU2569182C2
(ru)
*
|
2008-12-04 |
2015-11-20 |
КьюРНА,Инк.,US |
Лечение заболеваний, связанных с фактором роста эндотелия сосудов (vegf), посредством ингибирования природного антисмыслового транскрипта к vegf
|
|
KR101800833B1
(ko)
|
2009-03-20 |
2017-11-23 |
씨엘에스엔 래버러토리스, 인코퍼레이티드 |
폴리아민 유도체
|
|
US20120295811A1
(en)
|
2009-11-23 |
2012-11-22 |
Jean-Jacques Toulme |
Aptamers directed against the matrix protein-1 of type a influenza viruses and uses thereof
|
|
TWI510246B
(zh)
|
2010-04-30 |
2015-12-01 |
Molecular Partners Ag |
抑制ｖｅｇｆ－ａ受體交互作用的經修飾結合性蛋白質
|
|
KR20130136983A
(ko)
*
|
2010-09-24 |
2013-12-13 |
말린크로트 엘엘씨 |
치료 및/또는 진단용 나노담체의 목표화를 위한 압타머 접합체
|
|
US20150337308A1
(en)
|
2012-04-11 |
2015-11-26 |
Chu De Bordeaux |
Matrix metalloproteinase 9 (mmp-9) aptamer and uses thereof
|
|
AU2013340414B2
(en)
|
2012-10-23 |
2019-05-02 |
Caris Science, Inc. |
Aptamers and uses thereof
|
|
US10942184B2
(en)
|
2012-10-23 |
2021-03-09 |
Caris Science, Inc. |
Aptamers and uses thereof
|
|
EP2935628B1
(en)
|
2012-12-19 |
2018-03-21 |
Caris Life Sciences Switzerland Holdings GmbH |
Compositions and methods for aptamer screening
|
|
CN105264072B
(zh)
|
2013-03-22 |
2019-05-10 |
国立大学法人东京大学 |
针对il-17的适体及其用途
|
|
EA201690212A8
(ru)
|
2013-07-12 |
2016-08-31 |
Офтотек Корпорейшн |
Способы лечения или профилактики офтальмологических патологических состояний
|
|
CN105980615A
(zh)
|
2013-08-28 |
2016-09-28 |
卡里斯生命科学瑞士控股有限公司 |
寡核苷酸探针及其用途
|
|
SI3230316T1
(sl)
|
2014-12-11 |
2022-05-31 |
Bayer Healthcare Llc |
Zdravljenje starostne degeneracije makule z majhno aktivno horoidalno neovaskularizacijsko lezijo
|
|
EP3241903A4
(en)
|
2014-12-29 |
2018-07-04 |
Bonac Corporation |
Composition containing nucleic acid molecule stably
|
|
WO2016145128A1
(en)
|
2015-03-09 |
2016-09-15 |
Caris Science, Inc. |
Oligonucleotide probes and uses thereof
|
|
IL318703A
(en)
|
2015-06-29 |
2025-03-01 |
Caris Science Inc |
Therapeutic oligonucleotides
|
|
US10941176B2
(en)
|
2015-07-28 |
2021-03-09 |
Caris Science, Inc. |
Therapeutic oligonucleotides
|
|
WO2017046140A1
(en)
|
2015-09-18 |
2017-03-23 |
Bayer Pharma Aktiengesellschaft |
Treatment regimens for dr and rvo in dependence of the extent of retinal ischemia
|
|
US10731166B2
(en)
|
2016-03-18 |
2020-08-04 |
Caris Science, Inc. |
Oligonucleotide probes and uses thereof
|
|
US11697851B2
(en)
|
2016-05-24 |
2023-07-11 |
The Regents Of The University Of California |
Early ovarian cancer detection diagnostic test based on mRNA isoforms
|
|
IL298701B2
(en)
|
2016-05-25 |
2024-03-01 |
Caris Science Inc |
Oligonucleotide probes and uses thereof
|
|
EP3332812A1
(en)
|
2016-12-07 |
2018-06-13 |
Rheinische Friedrich-Wilhelms-Universität Bonn |
Nucleic acid-based assembly and use of the assembly in cancer therapy
|
|
TW201904610A
(zh)
|
2017-06-14 |
2019-02-01 |
德商拜耳製藥公司 |
用於治療新生血管型青光眼之非抗體vegf拮抗劑
|
|
US11931327B2
(en)
|
2017-07-04 |
2024-03-19 |
Daiichi Sankyo Company, Limited |
Drug for retinal degenerative disease associated with photoreceptor degeneration
|
|
WO2019210097A1
(en)
*
|
2018-04-25 |
2019-10-31 |
Vitrisa Therapeutics, Inc. |
Aptamers with stability, potency or half-life for enhanced safety and efficacy
|
|
GB202405551D0
(en)
|
2024-04-19 |
2024-06-05 |
Vvb Bio Pte Ltd |
Combination treatment
|